Kavya Ramkumar

2.0k total citations
20 papers, 545 citations indexed

About

Kavya Ramkumar is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Kavya Ramkumar has authored 20 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in Kavya Ramkumar's work include Lung Cancer Research Studies (7 papers), Phagocytosis and Immune Regulation (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Kavya Ramkumar is often cited by papers focused on Lung Cancer Research Studies (7 papers), Phagocytosis and Immune Regulation (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Kavya Ramkumar collaborates with scholars based in United States, Italy and Russia. Kavya Ramkumar's co-authors include Nouri Neamati, Erik Serrao, Srinivas Odde, Lauren A. Byers, C. Allison Stewart, Carl M. Gay, Li Shen, Robert J. Cardnell, Jing Wang and You-Hong Fan and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Clinical Cancer Research.

In The Last Decade

Kavya Ramkumar

20 papers receiving 534 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kavya Ramkumar United States 11 263 213 140 109 91 20 545
Francesca Morreale Italy 12 448 1.7× 130 0.6× 135 1.0× 96 0.9× 60 0.7× 15 610
Sheri Rogers United States 4 292 1.1× 88 0.4× 104 0.7× 97 0.9× 31 0.3× 7 477
Leanne Cartee United States 14 357 1.4× 226 1.1× 94 0.7× 32 0.3× 59 0.6× 27 646
Yasemin Saygıdeğer Türkiye 14 203 0.8× 136 0.6× 55 0.4× 50 0.5× 31 0.3× 37 490
H. Luke Carter United States 7 324 1.2× 147 0.7× 186 1.3× 154 1.4× 35 0.4× 7 596
Fonda M. Newcomb United States 8 289 1.1× 202 0.9× 115 0.8× 65 0.6× 82 0.9× 12 601
Michael J. Giffin United States 8 261 1.0× 181 0.8× 54 0.4× 70 0.6× 117 1.3× 11 599
Abel De La Rosa United States 14 644 2.4× 110 0.5× 112 0.8× 56 0.5× 135 1.5× 26 867
Teodora Pene Dumitrescu United States 11 318 1.2× 46 0.2× 88 0.6× 61 0.6× 32 0.4× 20 522
S. I. Foundling United States 8 337 1.3× 82 0.4× 121 0.9× 92 0.8× 28 0.3× 12 621

Countries citing papers authored by Kavya Ramkumar

Since Specialization
Citations

This map shows the geographic impact of Kavya Ramkumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kavya Ramkumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kavya Ramkumar more than expected).

Fields of papers citing papers by Kavya Ramkumar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kavya Ramkumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kavya Ramkumar. The network helps show where Kavya Ramkumar may publish in the future.

Co-authorship network of co-authors of Kavya Ramkumar

This figure shows the co-authorship network connecting the top 25 collaborators of Kavya Ramkumar. A scholar is included among the top collaborators of Kavya Ramkumar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kavya Ramkumar. Kavya Ramkumar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ramkumar, Kavya, Azusa Tanimoto, Carminia M. Della Corte, et al.. (2023). Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer. Clinical Cancer Research. 29(16). 3237–3249. 14 indexed citations
2.
Zhang, Bingnan, Yan Yang, C. Allison Stewart, et al.. (2023). Abstract 3196: Subtype-specific targeting of cell surfaceome with CAR T therapies in small cell lung cancer. Cancer Research. 83(7_Supplement). 3196–3196. 1 indexed citations
3.
Ramkumar, Kavya, C. Allison Stewart, Azusa Tanimoto, et al.. (2023). Abstract 6206: Combined inhibition of AXL and ATR enhances replication stress, cell death and immune response in small cell lung cancer. Cancer Research. 83(7_Supplement). 6206–6206. 2 indexed citations
4.
Samanta, Soma, Suhui Yang, Bikash Debnath, et al.. (2021). The Hydroxyquinoline Analogue YUM70 Inhibits GRP78 to Induce ER Stress–Mediated Apoptosis in Pancreatic Cancer. Cancer Research. 81(7). 1883–1895. 78 indexed citations
5.
Zhang, Bingnan, Kavya Ramkumar, Robert J. Cardnell, et al.. (2021). A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. British Journal of Cancer. 125(10). 1333–1340. 37 indexed citations
6.
Kundu, Kiran, Robert J. Cardnell, Bingnan Zhang, et al.. (2021). SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. Translational Lung Cancer Research. 10(11). 4095–4105. 29 indexed citations
7.
Kornepati, Anand, Clare Murray, Cody M. Rogers, et al.. (2021). 900 Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner. SHILAP Revista de lepidopterología. A944–A944. 2 indexed citations
8.
Cargill, Kasey R., C. Allison Stewart, Elizabeth M. Park, et al.. (2021). Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. SHILAP Revista de lepidopterología. 9(1). 33–33. 41 indexed citations
9.
Ramkumar, Kavya, C. Allison Stewart, Kasey R. Cargill, et al.. (2020). AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Molecular Cancer Research. 19(3). 485–497. 38 indexed citations
10.
Stewart, C. Allison, Carl M. Gay, Kavya Ramkumar, et al.. (2020). 1735P SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models. Annals of Oncology. 31. S1015–S1015. 10 indexed citations
11.
Ramkumar, Kavya, C. Allison Stewart, Carl M. Gay, et al.. (2020). 1736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer. Annals of Oncology. 31. S1015–S1016. 2 indexed citations
12.
Sen, Triparna, Carminia Maria Della Corte, Snezana Milutinovic, et al.. (2019). Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. Journal of Thoracic Oncology. 14(12). 2152–2163. 91 indexed citations
13.
Ramkumar, Kavya, Pan Tong, You-Hong Fan, et al.. (2019). Abstract 276: Targeting AXL sensitizes non-small cell lung cancer to ATR inhibitors by enhancing replication stress. Cancer Research. 79(13_Supplement). 276–276. 1 indexed citations
14.
Ramkumar, Kavya, Carminia Maria Della Corte, Lixia Diao, et al.. (2019). Abstract B024: Clinical, genomic, and immune landscape of the receptor tyrosine kinase AXL in non-small cell lung cancer. Molecular Cancer Therapeutics. 18(12_Supplement). B024–B024. 1 indexed citations
15.
Corte, Carminia Maria Della, Robert J. Cardnell, Li Shen, et al.. (2019). Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer. Annals of Oncology. 30. v716–v716. 4 indexed citations
16.
Corte, Carminia Maria Della, Robert J. Cardnell, Carl M. Gay, et al.. (2019). Abstract B064: The Aurora kinase A-inhibitor, alisertib, is a potential candidate for combination with immunotherapy in small cell lung cancer. Molecular Cancer Therapeutics. 18(12_Supplement). B064–B064. 2 indexed citations
17.
Ramkumar, Kavya, Erik Serrao, Srinivas Odde, & Nouri Neamati. (2010). HIV-1 integrase inhibitors: 2007-2008 update. Medicinal Research Reviews. 30(6). 890–954. 32 indexed citations
18.
Ramkumar, Kavya, Erik Serrao, Srinivas Odde, & Nouri Neamati. (2010). ChemInform Abstract: HIV‐1 Integrase Inhibitors: 2007—2008 Update. ChemInform. 42(4). 1 indexed citations
19.
Serrao, Erik, Srinivas Odde, Kavya Ramkumar, & Nouri Neamati. (2009). Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology. 6(1). 25–25. 125 indexed citations
20.
Ramkumar, Kavya, et al.. (2008). Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase Inhibitors. Bioorganic & Medicinal Chemistry. 16(19). 8988–8998. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesca Morreale Breakdown of academic impact, for papers by Sheri Rogers Breakdown of academic impact, for papers by Leanne Cartee Breakdown of academic impact, for papers by Yasemin Saygıdeğer Breakdown of academic impact, for papers by H. Luke Carter Breakdown of academic impact, for papers by Fonda M. Newcomb Breakdown of academic impact, for papers by Michael J. Giffin Breakdown of academic impact, for papers by Abel De La Rosa Breakdown of academic impact, for papers by Teodora Pene Dumitrescu Breakdown of academic impact, for papers by S. I. Foundling
Rankless by CCL
2026